Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-8448b6f56d-cfpbc Total loading time: 0 Render date: 2024-04-24T14:41:17.323Z Has data issue: false hasContentIssue false

10 - Autoimmune Liver Disease

Published online by Cambridge University Press:  08 August 2009

By
Andrea A. Gossard  and
Keith D. Lindor
Edited by
Zobair M. Younossi
Zobair M. Younossi
Affiliation:
Inova Fairfax Hospital, Annandale, VA
Get access

Summary

BACKGROUND

Autoimmune liver disease encompasses several disorders. Included in this category are primary sclerosing cholangitis (PSC), primary biliary cirrhosis (PBC), and autoimmune hepatitis (AIH). There are also several “overlap syndromes” which encompass two of these diseases in combination. In this chapter, we will describe these liver conditions, including the typical clinical presentation, the diagnostic criteria, management, and potential complications. We will also discuss briefly the role of orthotopic liver transplantation.

PRIMARY SCLEROSING CHOLANGITIS

Primary sclerosing cholangitis (PSC) is a chronic, cholestatic liver disease of unknown etiology. Several potential causes have been described. These include disordered immunoregulation; which may involve altered T-cell subsets, abnormal T-cell suppressor function, circulating immune complexes, and/or abnormal complement levels; infections and bacterial products; or portal bacteremia. The disease leads to diffuse inflammation and fibrosis of the biliary tree which ultimately causes biliary cirrhosis and portal hypertension.

Clinical Presentation

Clinically, patients with PSC will often present with an incidental finding of elevated liver tests in a cholestatic profile (elevated alkaline phosphatase). The majority (70%) of patients will also have inflammatory bowel disease (IBD), typically chronic ulcerative colitis. Fifteen to 44% of patients may be entirely asymptomatic. Others may present with symptoms of cholestasis such as fatigue, jaundice, hyperpigmentation, or pruritus (Table 10.1). A subset may even have evidence of cholangiocarcinoma at the time of initial presentation.

Diagnosis

The diagnosis of PSC is typically made in the setting of liver tests elevated in a cholestatic profile and an abnormal cholangiogram. Autoantibodies may also be present (Table 10.2).

Type
Chapter
Information
Practical Management of Liver Diseases , pp. 155 - 173
Publisher: Cambridge University Press
Print publication year: 2008

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Angulo, P and Lindor, KD. Primary sclerosing cholangitis. Hepatol 1999;30(1):325–32.CrossRefGoogle Scholar
Angulo, P and Lindor, KD. Primary biliary cirrhosis and primary sclerosing cholangitis. Clin Liver Dis, 1999;3(3):529–70.CrossRefGoogle Scholar
Mendes, F and Lindor, KD. Primary sclerosing cholangitis. Clin Liver Dis, 2004;8(1):195–211.CrossRefGoogle Scholar
Vierling, J.M. In: Zakim &, Boyer, eds. Hepatology, 2003;1221.
Broome, U, Glaumann, H, Lindstom, E, Loof, L, Almer, S, Prytz, H, Sandberg-Gertzen, H, Lindgren, S, Fork, FT, Jarnerot, G, and Olsson, R. Natural history and outcome in 32 Swedish patients with small duct primary sclerosing cholangitis. J Hepatol, 2002;36:586–589.CrossRefGoogle ScholarPubMed
Burak, K, Angulo, P, Pasha, TM, Egan, K, Petz, J, and Lindor, KD. Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis. Am J Gastroenterol, 2004;99(3):523–6.CrossRefGoogle Scholar
Hay, JE. The metabolic bone disease of primary sclerosing cholangitis. Hepatol, 1991;14(2):257–261.CrossRefGoogle Scholar
Angulo, P, Therneau, TM, Jorgensen, R, DeSotel, CK, Egan, KS, Dickson, ER, Hay, JE, and Lindor, KD. Bone disease in patients with primary sclerosing cholangitis: prevalence, severity and prediction of progression. J Hepatol, 1998;29(5):729–735.CrossRefGoogle Scholar
Ponsioen, C, Lam, K, Milligen, Wit AW, Huibregtse, K, and Tytgat, GN. Four year experience with short term stenting in primary sclerosing cholangitis. Am J Gastroenterol, 1999;94:2403–2407.CrossRefGoogle Scholar
Harnois, D, Angulo, P, Jorgensen, RA, LaRusso, NF, and Lindor, KD. High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis. Am J Gastroentero, 2001;96:1558–1562.CrossRefGoogle ScholarPubMed
Mitchell, SA, Bansi, DS, Hunt, N, Bergmann, K, Fleming, KA, and Chapman, RW. A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis. Gastroenterology, 2001;121:900–907.CrossRefGoogle ScholarPubMed
Faust, TW. Recurrent primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis after transplantation. Semin Liver Dis, 2000;20:481–495.CrossRefGoogle ScholarPubMed
Graziadei, IW, Wiesner, RH, Batts, KP, Marotta, PJ, LaRusso, NF, Porayk, MK, Hay, JE, Gores, GJ, Charlton, MR, Ludwig, J, Poterucha, JJ, Steers, JL, and Krom, RA. Recurrence of primary sclerosing cholangitis following liver transplantation. Hepatol, 1999;29:1050–1056.CrossRefGoogle ScholarPubMed
Broome, U, Lofberg, R, Veress, B, and Ericksson, LS. Primary sclerosing cholangitis and ulcerative colitis: evidence for increased neoplastic potential. Hepatol, 1995;22:1404–1408.Google ScholarPubMed
Michieletti, P, Wanless, IR, Katz, A, Scheuer, PH, Yeaman, SJ, Bassendine, MF, Palmer, JM, and Heathcote, EJ. Gut, 1994;35:260.CrossRef
Gershwin, ME. The natural history of primary biliary cirrhosis: of genes and cooperation. J Hepatol, 2001;35:412–415.CrossRefGoogle ScholarPubMed
Parikh-Patel, A, Gold, EB, Worman, H, Krivy, KE, and Gershwin, ME. Risk factors for primary biliary cirrhosis in a cohort of patients from the United States. Hepatol, 2001;33:16–21.CrossRefGoogle Scholar
Springer, J, Cauch-Dudek, K, O'Rourke, K, Wanless, IR, and Heathcote, EJ. Asymptomatic primary biliary cirrhosis: a study of its natural history and prognosis. Am J Gastroenterol, 1999; 47–53.CrossRefGoogle ScholarPubMed
Cauch-Dudek, K, Abbey, S, Stewart, , and Heathcote, EJ. Fatigue in primary biliary cirrhosis. Gut, 1998;43:705–710.CrossRefGoogle ScholarPubMed
Talwalker, JA, Souto, E, Jorgensen, RA, and Lindor, KD. Natural history of pruritus in primary biliary cirrhosis. Clin Gastro and Hepatol, 2003;1(4):297–302.CrossRefGoogle Scholar
Talwalkar, JA, Lindor, KD. in Zakim, and Boyer, , eds. Hepatology, 2005.
Kim, WR, Poterucha, JJ, Jorgensen, RA, Batts, KP, Homburger, HA, Dickson, ER, Krom, RA, and Wiesner, RH. Does antimitochondrial antibody status affect response to treatment in patients with primary biliary cirrhosis? Outcomes of ursodeoxycholic acid therapy and liver transplantation. Hepatology, 1997;26(1):22–6.CrossRefGoogle Scholar
Zein, CO, Angulo, P, and Lindor, KD. When is liver biopsy needed in the diagnosis of primary biliary cirrhosis?Clin Gastroenterol Hepatol, 2003;1(2):89–95.CrossRefGoogle Scholar
Ludwig, J, Czaja, A, Dickson, ER, Russo, NF, Wiesner, RH. Manifestations of nonsuppurative cholangitis in chronic hepatobiliary diseases: morphologic spectrum, clinical correlations and terminology. Liver, 1984;4:105.CrossRefGoogle ScholarPubMed
Scheuer, PJ. Primary biliary cirrhosis. Proc R Soc Med, 1967;60:1257–1260.Google ScholarPubMed
Menon, KVN, Angulo, P, Weston, S, Dickson, ER, and Lindor, KD. Bone disease in primary biliary cirrhosis: independent indicators and rate of progression. J Hepatol, 2001;35:316–323.CrossRefGoogle ScholarPubMed
Leuschner, U. Primary biliary cirrhosis–presentation and diagnosis. Clin Liver Dis, 2003;7:741–58.CrossRefGoogle ScholarPubMed
Caballeria, L, Pares, A, Castells, A, Gines, A, Bru, C, and Rodes, J. Hepatocellular carcinoma in primary biliary cirrhosis: similar incidence to that in hepatitis C virus-related cirrhosis. Am J Gastroenterol, 2001;96(4):1160–3.Google Scholar
Lindor, KD. Management of osteopenia of liver disease with special emphasis on primary biliary cirrhosis. Semin Liver Dis, 1993;13(4);367–373.CrossRefGoogle Scholar
Jorgensen, RA, Lindor, KD, Sartin, JS, LaRusso, NF, and Wiesner, RH. Serum lipid and fat-soluble vitamin levels in primary sclerosing cholangitis. J Clin Gastroenterol, 1995;20(3) 215–9.CrossRefGoogle Scholar
Angulo, P, Batts, KP, Therneau, TM, Jorgensen, RA, Dickson, ER, and Lindor, KD. Long-term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis. Hepatol, 1999;29(3):644–647.CrossRefGoogle Scholar
Lindor, KD, Therneau, TM, Jorgensen, RA, Malinchoc, M, Dickson, ER. Effects of ursodeoxycholic acid on survival in patients with primary biliary cirrhosis. Gastro- enterology, 1996;110(5):1515–8.CrossRefGoogle Scholar
Goulis, J, Leandro, G, and Burroughs, AK. Randomised controlled trials of urso- deoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis. Lancet 25, 1999;354(9184):1053–60.CrossRefGoogle Scholar
Poupon, RE. Ursodeoxycholic acid for primary biliary cirrhosis: lessons from the past-issues for the future. J Hepatol, 2000;32:689.Google ScholarPubMed
Neuberger, J. Recurrent primary biliary cirrhosis. Liver Transplantation, 2003;9(6):539–46.CrossRefGoogle Scholar
Kirk, AP, Jain, S, Pocock, S, Thomas, HC and Sherlock, S. Late results of the Royal Free Hospital prospective controlled trial of prednisolone therapy in hepatitis B surface antigen negative chronic active hepatitis. Gut, 1980; 21:78.CrossRefGoogle Scholar
Cjaza, AJ and Freese, DK. Diagnosis and treatment of autoimmune hepatitis. Hepatology, 2002;36:479–497.Google Scholar
Ben-Ari, Z, and Cjaza, AJ. Autoimmune hepatitis and its variant syndromes. Gut, 2001;49:589–594.CrossRefGoogle ScholarPubMed
Czaja, AJ and Manns, MP. The validity and importance of subtypes in autoimmune hepatitis – a point of view. Am J Gastroenterol, 1995;90:1206–11.Google ScholarPubMed
Soloway, RD, Summerskill, WH, Baggenstoss, AH, GEall, MG, Gitnick, GL, Elveback, IR and Schoenfield, LJ. Gastroenterology, 1972;63:828.
,AASLD Practice Guidelines, Hepatology 2002;36:479.CrossRef
Czaja, AJ. Treatment of autoimmune hepatitis. Semin Liver Dis, 2002;22,365–377.CrossRefGoogle ScholarPubMed
Czaja, AJ, Davis, GL, Ludwig, J, Taswell, HF. Complete resolution of inflammatory activity following corticosteroid treatment of HBsAG-negative chronic active hepatitis. Hepatology, 1984;4:622–7.CrossRefGoogle ScholarPubMed
Czaja, AJ, Carpenter, HA. Histological features associated with relapse after corticosteroid withdrawal in type 1 autoimmune hepatitis. Liver International, 2003;23:116.CrossRefGoogle ScholarPubMed
Heneghan, MA, and McFarlane, Ig. Current and novel immunosuppressive therapy for autoimmne hepatitis. Hepatology, 2002;35:7–13.CrossRefGoogle Scholar
Czaja, A. Treatment of autoimmune hepatitis. Semin Liver Dis, 2002;22:365–78.CrossRefGoogle ScholarPubMed
Czaja, A. The variant forms of autoimmune hepatitis. Ann Intern Med, 1996;125:588–598.CrossRefGoogle ScholarPubMed
Joshi, S, Cauch-Dudek, K, Wanless, IR, Lindor, KD, Jorgensen, R., and Heathcote, EJ. Primary biliary cirrhosis with additional features of autoimmune hepatitis: response to therapy with ursodeoxycholic acid. Hepatology, 2002;35(2):409–413.CrossRefGoogle Scholar
Bjornsson, E, Boberg, KM, Cullen, S, Fleming, K, Clausen, O, Fausa, O, Schrumpf, E, and Chapman, R. Patients with small duct primary sclerosing cholangitis have a favourable long term prognosis. Gut, 2002;51:731–735.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×